squamous cell anal carcinoma
Oncology · 2025–2026
2decisions
1medicine
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| retifanlimab Treatment of inoperable locally recurrent or metastatic squamous cell anal carcinoma (SCAC) not previously treated with systemic chemotherapy, in combination… | Mar 2026 | Recommended with restriction | input received Rare Cancers Australia |
| retifanlimab Treatment of inoperable locally recurrent or metastatic squamous cell anal carcinoma (SCAC) not previously treated with systemic chemotherapy, used in… | Nov 2025 | Deferred | input received Rare Cancers Australia |
Who spoke
Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.